GlassScriptPhysician profile
Tyler Michael Burns
NPI 1609654755
$4,560.40
in general payments reported to CMS, 2019-2025
18 companies · $50.98 in 2025
The $50.98 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $688 · 2024: $3,821 · 2025: $50.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.92 |
| Education | $162.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $962.14 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $577.02 | 2023-2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $432.71 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $351.46 | 2023-2024 | Caplyta |
| Lundbeck LLC | $314.15 | 2023-2024 | Rexulti |
| Corium, LLC | $310.27 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $254.07 | 2023-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $227.88 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Tris Pharma INC | $205.18 | 2023-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Almatica Pharma LLC | $202.52 | 2023-2024 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $202.26 | 2024 | Fanapt, Hetlioz |
| Indivior INC. | $142.10 | 2023-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $105.10 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $92.96 | 2023-2024 | Trintellix |
| Noven Therapeutics, LLC | $75.41 | 2024 | Xelstrym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45.67 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $33.86 | 2023-2024 | Quviviq |
| Biogen, INC. | $25.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.